Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

486 results about "Ige reactivity" patented technology

Immunoglobulin E (IgE) are antibodies produced by the immune system. If you have an allergy, your immune system overreacts to an allergen by producing antibodies called Immunoglobulin E (IgE). These antibodies travel to cells that release chemicals, causing an allergic reaction.

Latex duplex immunochromatography test strip for rapidly identifying and detecting TGEV and PEDV and preparation method of latex duplex immunochromatography test strip

The invention belongs to the technical field of biology, and particularly relates to a latex duplex immunochromatography test strip for rapidly identifying a porcine transmissible gastroenteritis virus (TGEV) and a porcine epidemic diarrhea virus (PEDV) and a preparation method of the latex duplex immunochromatography test strip. Soluble TGEV N protein and PEDV N protein with immunogenicity and reactivity are respectively obtained by utilizing a prokaryotic expression system, the soluble TGEV N protein and the soluble PEDV N protein are used as immunogenicity to immunize mice, and specific monoclonal antibodies of the TGEV N protein and the PEDV N protein are respectively obtained by utilizing cell fusion and subcloning screening technologies. The antibody variable region gene sequence is obtained by using a nested PCR amplification technology, and can be subsequently obtained by using a gene engineering or protein engineering method. Then, the latex duplex immunochromatography test strip for detecting TGEV and PEDV, which is convenient, rapid and high in sensitivity, and the preparation method are researched and developed on the basis of specific monoclonal antibodies of TGEV N protein and PEDV N protein.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Monoclonal antibody aiming at bovine nodular skin disease virus L1R protein

The invention belongs to the technical field of immunology and in vitro diagnosis, and relates to a monoclonal antibody aiming at bovine nodular skin disease virus (LSDV) L1R protein. According to the invention, the LSDV recombinant L1R protein with deletion of a transmembrane region (182-204aa) is obtained through expression; after a mouse is immunized by the protein, a monoclonal antibody 8D5 which is good in reactivity and specificity and aims at the LSDV L1R protein is screened out; heavy chain and light chain variable region sequences for coding the monoclonal antibody 8D5 are obtained; the monoclonal antibody 8D5 can be subjected to specific reaction with LSDV L1R protein, the recombinant protein L1R can be specifically recognized by bovine LSDV positive serum, meanwhile, the monoclonal antibody 8D5 can be used for establishing an LSDV ELISA antibody detection method, and a foundation is laid for LSDV diagnostic technology and vaccine research and development.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

GPRC5D single domain and humanized antibody thereof

The invention provides the GPRC5D single domain and the humanized antibody thereof, the GPRC5D single domain and the humanized antibody thereof have relatively strong binding activity and reaction specificity, also have good species cross reactivity, are of great significance in research and development in different species models, and are beneficial to acceleration of a transformation process from a laboratory to clinic. The antibody sequence provided by the invention can be used for constructing CAR-T, and can be used for treating multiple myeloma.
Owner:SHENZHEN HAOSHI BIOTECHNOLOGY CO LTD

Fecal microbiota transplantation overcomes resistance to immunotherapy in gastrointestinal cancer patients

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.
Owner:SHENZHEN XBIOME BIOTECH CO LTD

Preparation method and application of autoreactive animal model

PendingCN120519516ACompounds screening/testingHydrolasesDiseaseAntibody Classes
The invention discloses a preparation method and application of a self-reactive animal model. An autoreactive animal model is constructed based on an SWHEL system, it is found through the model that MTCH2 is a key target for regulating and controlling B cell autoreactivity, deletion of MTCH2 will cause generation of a large number of autoreactive B cells subjected to antibody category conversion, the disease risk is increased, and a basis is provided for research of B cell autoreactivity related mechanisms.
Owner:BEIJING HOSPITAL

Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds. When compared with trastuzumab, the antibody of the present disclosure exhibits better killing ability for HER2-unexpressed cancer cells which have non-reactivity (or resistance) to the trastuzumab antibody or have reduced sensitivity. In addition, when the anti-HER2 antibody of the present disclosure is administered in combination with trastuzumab, a synergistic killing ability is achieved for cancer cells on which the trastuzumab antibody acts. Therefore, a composition of the present disclosure can be very usefully used for combined administration with the trastuzumab antibody for the treatment of cancer, or for the treatment of cancer not treated with trastuzumab.
Owner:GC CELL CORP

Novel magnetic particle chemiluminiscence detection kit for A beta 1-42 and preparation method of novel magnetic particle chemiluminiscence detection kit

The invention relates to the technical field of A beta 1-42 detection, and discloses a novel magnetic particle chemiluminescence detection kit for A beta 1-42 and a preparation method of the novel magnetic particle chemiluminescence detection kit for A beta 1-42. A double-antibody sandwich method is adopted, A beta 1-42 and reagents form a sandwich structure compound when a sample is incubated with a reagent R1 and a reagent R2, and the sandwich structure compound is used for detecting A beta 1-42. The acridinium ester in the reagent can emit light with specific wavelength under the action of excitation liquid, a full-automatic chemiluminescence immunoassay analyzer is used for detecting a luminescence value, and the content of Abeta1-42 is measured according to a standard curve of concentration-luminescence value of Abeta1-42. According to the present invention, the damage of the antibody and biotin coupling process and the labeled antibody and marker coupling process to the immunocompetence of the Abeta1-42 mouse anti-human IgG antibody is avoided, the reactivity and the sensitivity of the detection are significantly improved, the reaction time is shortened, particularly, the sensitivity is significantly higher than that of other methodologies, and the detection rate of the Abeta1-42 in the human serum is improved.
Owner:ANHUI IPROCOM BIOTECH CO LTD

Antibody-drug conjugate precursors and synthetic intermediates thereof

Provided are: a method for improving the stability of an antibody-drug conjugate in a living body; and a conjugate precursor for obtaining a stabilized antibody-drug conjugate. Specifically, the present invention provides an antibody-drug conjugate precursor represented by general formula (I): Z-L-D (I) or a salt thereof, a synthetic intermediate thereof or a salt thereof, and the like. [In the formula, Z is a reactive group capable of reacting with a functional group present in an antibody or a modified antibody, D is an antitumor drug residue obtained by removing one hydrogen atom or one hydroxyl group from any position of an antitumor drug molecule, an analog thereof, or a derivative thereof, L is a linker linking Z and D, and n is an integer from 1 to 2. And at least one of D and L has at least one lactone group as a substituent or protecting group at an arbitrary position].
Owner:UBE CORPORATION

Detection of autoantibodies against NR1

The present disclosure provides systems and methods for detecting anti-NMDAR autoantibodies based on the strong affinity of the anti-NMDAR autoantibodies to a plurality of non-random anti-NR1s coupled to a solid support. The present disclosure also provides methods of treatment for anti-NMDAR pathology by the therapeutic anti-NMDAR antibody ART5803. The present disclosure also provides methods and systems for screening and predicting potential responsiveness to ART5803 therapy.
Owner:ARIALYS THERAPEUTICS INC

Antibody-drug conjugate containing thiazolo[5,4-b]pyridine structure and use thereof

The present invention relates to a new thiol-reactive coupling moiety as shown in formula (I), a linker containing the coupling moiety, a linker-payload conjugate, an antibody-drug conjugate based on the linker and the use thereof, and further relates to a pharmaceutical composition containing the antibody-drug conjugate, and the use of the antibody-drug conjugate for treating and / or preventing a disease.
Owner:BEIJING TIDE PHARMACEUTICAL CO LTD

Binding proteins and engineered cells specific for neoantigens and uses thereof

The present disclosure provides compositions and methods for targeting neoantigens, for example, to treat or prevent cancer. The disclosed embodiments include binding proteins, such as T cell receptors, that bind to the neoantigen: HLA complex. The binding protein further comprises a construct comprising a fusion protein of the CD95 extracellular domain and the CD137 intracellular signaling domain (Fas-41BB), and a CDS coreceptor alpha or beta chain. The disclosed binding proteins are highly sensitive to antigens and are capable of inducing activation of host T cells at low concentrations of peptide antigens. In certain embodiments, binding proteins of the present disclosure (i) have no alloreactivity, substantially no alloreactivity, and / or low risk of alloreactivity, to amino acid sequences from human proteomes and / or (ii) to human HLA alleles. Polynucleotides encoding such binding proteins can be introduced into host cells, such as T cells, and the cells can be used in immunotherapy for the treatment of various cancers.
Owner:AIFENI T MEDICAL +1

Diagnostic kit for skin comprising antibody for staphylococcus aureus protein a

The present invention relates to an antibody specific for Staphylococcus aureus protein A, and to a composition or kit comprising same for detecting Staphylococcus aureus or diagnosing skin conditions. The monoclonal antibody according to the present invention is highly reactive to antigens, and, particularly, can detect antigens rapidly and accurately even at low concentrations due to two antibodies of different CDRs having been combined and used as capture and detection antibodies, thus allowing the monoclonal antibody to be used in rapid self-diagnostic kits and the like. In using the monoclonal antibody, the degree of proliferation of Staphylococcus aureus on the skin surface and the like can be visually checked, abnormal states of the skin, such as inflammation and excessive immune response, can be diagnosed, incidence probability and persistence of related diseases can be predicted, and subsequent treatment methods can be determined.
Owner:KOLMAR KOREA

Degrader antibody conjugates and uses thereof

The invention provides antibody conjugate compositions of Formula I comprising an antibody linked by conjugation to one or more target protein binder and VHL ligand (TPI-VHL) moieties. The invention also provides TPI-VHL derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the antibody conjugates through a linker or linking moiety. The invention further provides methods of treating diseases and disorders such as cancer with the antibody conjugates.
Owner:FIREFLY BIO INC

Veto cells generated from memory T cells

ActiveUS12391916B2Immunoglobulin superfamilyLectin superfamilyAntigenTolerance induction
A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and / or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
Owner:YEDA RES & DEV CO LTD

Neoantigens and uses thereof for treating cancer

Systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen are provided. Sequencing reads are obtained from samples from the subject representative of the cancer. A human leukocyte antigen type and a plurality of clones is determined from the sequencing reads. For each clone, an initial frequency Xα in the one or more samples is determined and a corresponding clone fitness score of the clone is computed, thereby computing clone fitness scores. Each such fitness score is computed by identifying neoantigens in the respective clone, computing a recognition potential for each neoantigen, and determining the corresponding clone fitness score of the respective clone as an aggregate of these recognition potentials. A total fitness, quantifying the likely responsiveness of the subject to the regimen, is computed by summing the clone fitness scores across the plurality of clones.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +2

Single-domain antibody capable of specifically recognizing GPRC5D

The invention provides a single-domain antibody capable of specifically recognizing GPRC5D, which has relatively strong binding activity and reaction specificity, also has good species cross reactivity, is of great significance to research and development in different species models, and is beneficial to acceleration of a transformation process from a laboratory to clinic. The antibody sequences A12 and C07 provided by the invention can be used for constructing chimeric antigen receptor T cells, and the chimeric antigen receptor T cells can be used for treating multiple myeloma.
Owner:SHENZHEN HAOSHI BIOTECHNOLOGY CO LTD

Anti-porcine pseudorabies virus glycoprotein gB antibody and application thereof

ActiveCN120399043ABiological material analysisImmunoglobulins against virusesAntigenPseudorabies virus glycoproteins
The invention belongs to the technical field of immunological detection, and particularly relates to an antibody for resisting porcine pseudorabies virus glycoprotein gB and application of the antibody. The antibody is a first antibody or a second antibody, amino acid sequences of light chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of heavy chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.8-10; the amino acid sequences of light chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.13-15, and the amino acid sequences of heavy chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.18-20. The antibody and the PRV glycoprotein gB have good reactivity, recognition specificity and binding sensitivity, the detection sensitivity and accuracy of the gB protein or the anti-gB protein antibody are improved, and an antibody tool with excellent performance is provided for qualitatively or quantitatively evaluating the immune effect of swine herd vaccines and detecting the content of porcine pseudorabies virus antigens in a sample.
Owner:WEITAIKE BIOTECHNOLOGY (WUHAN) CO LTD +1

Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof

The invention provides a composition, and method of use thereof, comprising self-antigen displaying nanoparticles to target auto-reactive immune components for treating and / or preventing the autoimmune diseases associated therewith. The nanoparticles can also be loaded with cytotoxic drugs for targeted cell killing or with immune-tolerizing compounds to normalize the immune regulation.
Owner:RGT UNIV OF CALIFORNIA

T cell epitope peptide of Oratosquilla oratoria allergen tropomyosin and application of T cell epitope peptide

The invention provides a T cell epitope peptide of Oratosquilla oratoria allergen tropomyosin and application thereof, the T cell epitope peptide is any one or more of the following epitope polypeptides, and the amino acid sequences of the epitope polypeptides are shown as SEQ ID NO: 1-4. According to the invention, 10 T cell epitope peptides are predicted by using bioinformatics software. Four T cell epitope peptides without IgE reactivity are identified by combining a CD4 + T cell proliferation experiment with the release level of IL-2 and a serological experiment; the T-cell epitope tandem peptide with immune tolerance potential is designed based on the T-cell epitope peptide and can be developed into a desensitization preparation for preventing or treating shrimp allergy, and a new strategy is provided for developing a food allergy immunotherapy.
Owner:XIAMEN OCEAN VOCATIONAL & TECH COLLEGE

Method for determining resistance to immune checkpoint inhibitors

PCT designated stage expiredWO2024254435A2Microbiological testing/measurementDisease diagnosisHaplogroupCell biology
Provided are methods for determining responsiveness to immune checkpoint inhibition. The methods involve determining a mitochondrial haplogroup for an individual who has been diagnosed with cancer. Based on the determination of the mitochondrial haplogroup, an immune checkpoint inhibition therapy can be selected for the individual with improved likelihood of efficacy compared to selection of an immune checkpoint inhibition therapy selected without the mitochondrial haplogroup analysis. The mitochondrial haplogroup analysis can be performed prior to initiating an immune checkpoint therapy.
Owner:NEW YORK UNIV

Preparation method and application of tetravalent hand-foot-and-mouth disease subunit-new adjuvant vaccine

The invention discloses a preparation method and application of a tetravalent hand-foot-and-mouth disease subunit-new adjuvant vaccine, and relates to the technical field of hand-foot-and-mouth disease vaccines. VP1 proteins of EV-A71, CV-A16, CV-A10 and CV-A6 are expressed through an insect cell-baculovirus system, the VP1 proteins are purified through a nickel affinity chromatography column and mixed with an MF59 adjuvant to prepare a tetravalent vaccine, in-vivo evaluation of mice is conducted, and meanwhile the immunogenicity and protection efficacy of the tetravalent VP1 protein vaccine and the immunogenicity and protection efficacy of a monovalent VP1 protein vaccine are compared. Immune results show that compared with a VP1 monovalent vaccine, all serum of a mouse inoculated with the tetravalent VP1 protein vaccine shows strong reactivity to all captured antigens. Therefore, the results show that the prepared tetravalent subunit-new adjuvant vaccine is a promising broad-spectrum vaccine.
Owner:JIANGSU CONVAC BIO TECH CO LTD +1

Specific binding polypeptide of targeted cell membrane receptor Fc epsilon RI alpha and application of specific binding polypeptide

The invention provides a specific binding polypeptide of a targeted cell membrane receptor Fc epsilon RI alpha and application of the specific binding polypeptide. The amino acid sequence of the polypeptide is shown in any one of (I) SEQ ID NO: 1-6; (II) an amino acid sequence with at least 90% identity as shown in any one of SEQ ID NO: 1-6, and is specifically combined with a cell membrane receptor Fc epsilon RI alpha. Experimental results show that the Fc [epsilon] RI [alpha] specific binding polypeptide can inhibit IgE-mediated mast cell dependent anaphylaxis to a certain extent, which prompts that the Fc [epsilon] RI [alpha] specific binding polypeptide has a certain inhibition effect on IgE-mediated I-type anaphylaxis, and lays a foundation for further research and development of novel biological targeting drugs for treating allergic diseases.
Owner:GENERAL HOSPITAL OF SOUTHERN THEATRE COMMAND OF PLA

Multifunctional manganese-based hybrid nano-platform based on NK cell membrane modification as well as preparation method and application of multifunctional manganese-based hybrid nano-platform

The invention relates to a multifunctional manganese-based hybrid nano-platform based on NK cell membrane modification and a preparation method and application thereof, by selecting a highly branched dendritic polymer PSeSeS modified by a diselenide bond as a carrier and partially modifying mPEG and phenylboronic acid, water solubility and stability are improved, and the material is endowed with specific reactivity in a tumor microenvironment. Furthermore, potassium permanganate is reduced by using the tail end of PSeS and a tertiary amine group to generate MnO nano-particles, so that the low-oxygen environment of tumors is relieved, the photothermal therapy is enhanced, and meanwhile, active oxygen can be generated. Then doxorubicin and cGAMP are loaded, chemotherapy and immunotherapy are combined, and the tumor recognition and removal capacity of an immune system is improved; nK cell membrane modification is further adopted, so that the targeting property and the in-vivo stability are improved. The nano platform overcomes the defects of poor tumor microenvironment responsiveness, weak targeting, inaccurate drug release, single treatment mode and the like in the prior art, and can significantly improve the effect and safety of liver cancer treatment.
Owner:BEOGENE BIOTECH GUANGZHOU

PD-1 non-blocking clearing antibody and use thereof

A PD-1 non-blocking antibody and a use thereof. The present invention relates to a clearing antibody, which specifically binds with high affinity to a PD-1, but does not block binding of the PD-1 and a ligand thereof, thereby achieving the effect of removing autoreactive and alloreactive T cells and B cells. Therefore, the clearing antibody is used for treating autoimmune diseases, rejection reaction of organ and cell transplantation, and inflammations.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

DAR1 antibody drug conjugate as well as preparation method and application thereof

The invention provides a DAR1 antibody drug conjugate as well as a preparation method and application thereof, a drug is connected to a sulfydryl reactive load, and the sulfydryl reactive load is coupled with a Fab of an antibody or a sulfydryl of a hinge structural domain; the sulfydryl reactive load is a reactive group coupled with double sulfydryl; the medicine is methyl auristatin E; the sulfydryl reactive load is a reactive group containing a sulfur bridge group. The product prepared by the preparation process of the DAR1 antibody drug conjugate is high in uniformity, simple to operate and low in cost, and has important application value in production of the antibody drug conjugate.
Owner:WUXI XDC (SHANGHAI) CO LTD

Medicament for treatment and / or prevention of cancer

The present invention relates to a medicament for treatment and / or prevention of cancer, comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, and a MAPK pathway inhibitor together or separately in combination.
Owner:TORAY INDUSTRIES INC

N-arylpyrazole nod2 agonists as promoters of immune checkpoint inhibitor therapy

The disclosure provides the development of enantiomer-specific 7V-arylpyrazole dipeptides as novel N0D2 agonists which are effective at promoting immune checkpoint inhibitor therapy requiring N0D2 for activity. Given the significant functions of N0D2 in innate and adaptive immunity, these novel agonists afford new therapeutic compounds for a variety of NOD2-responsive diseases.
Owner:THE SCRIPPS RES INST +1

MRNA (messenger ribonucleic acid) and preparation method, application and vaccine thereof

The invention belongs to the field of biology, and discloses an mRNA (messenger ribonucleic acid) with a nucleotide sequence as shown in SEQ ID NO.3. Antiserum of a strain (A / chick / Gansuu / 28 / 2024) corresponding to the mRNA has relatively good reactivity with other strains and poorer reaction with a current vaccine strain RE-13, the branched strain is a current epidemic strain, and the mRNA prepared from the HA gene of the strain has the advantage of strong protection; the invention also aims to provide the mRNA, application thereof and a vaccine.
Owner:CHINA AGRI UNIV SANYA RES INST +1

Anti-TLR7 antibody or antigen-binding fragment thereof, pharmaceutical composition and use thereof

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.
Owner:BEIJING SYNTHETIC VACCINE BIOSCIENCES CO LTD

Homogeneous antibody-conjugates with high payload loading

The invention concerns homogenous antibody-conjugates with high payload loading (high DAR) obtained by site-specific conjugation to a single antibody N-glycan. The conjugates according to the invention are homogeneous, i.e. have a DAR at or close to the theoretical DAR with a narrow distribution, and do not require any genetic modification of the antibody. The invention further concerns a modular, non-genetic preparation method for such conjugates, involving three simple steps and starting from any antibody. These steps are (a) enzymatic remodeling of the glycan to give an antibody functionalized with two or four click probes per antibody, (b) strain-promoted cycloaddition with a multivalent, bifunctional reagent comprising one cyclic alkyne and at least two click probes that are not reactive towards the cyclic alkyne, and (c) inverse electron-demand Diels-Alder cycloaddition of the click probes with branched linker-drug constructs comprising one cyclic alkyne or strained alkene, connected to one or more payloads preferably connected through a cleavable linker. The resulting conjugates, with DAR6 or higher, are rapidly generated with high homogeneity and with surprising stability. In addition, HIC profiles of the resulting ADCs indicate small relative retention time and therefore show high potential in the targeting of tumour cells and / or the treatment of cancer.
Owner:SYNAFFIX BV